SelectImmune Pharma AB is a Swedish AB, operating in the Other research and experimental development on natural sciences and engineering sector. Incorporated in 2017, the company has 2 employees and reported revenue of SEK 0 in its latest annual filing.
Firman tecknas av styrelsen Firman tecknas av Godaly, Gabriela Sofia Victoria i förening med en av Svanborg, Marianne Catharina Zetterberg, Jan Gustaf Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolaget ska bedriva konsultverksamhet inom medicin samt forskning och utveckling av läkemedel, särskilt inom området infektioner, ävensom idka därmed förenlig verksamhet.
(no translation available)
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
In its most recent annual report (2023), SelectImmune Pharma AB reported revenue of SEK 0. The figures on this page draw on 5 annual filings covering 2019 to 2023. The bottom line showed a net loss of SEK 8.6m.
At the end of 2023, equity financed 61.8% of the balance sheet, and current assets covered short-term debt 2.2 times.
Frequently asked questions
What is the Org number of SelectImmune Pharma AB?
SelectImmune Pharma AB is registered with Bolagsverket / SCB under Org 5591046874.
How many employees does SelectImmune Pharma AB have?
SelectImmune Pharma AB employs 2 people as of the latest annual report.
Who is the CEO of SelectImmune Pharma AB?
Gabriela Sofia Victoria Godaly is the CEO of SelectImmune Pharma AB, in role since 2020.
Who is the chairman of SelectImmune Pharma AB?
Marianne Catharina Svanborg chairs the board of SelectImmune Pharma AB, in role since 2020.
